VIscher appointed managing associates Basile Walder, Elias Mühlemann and Luzius Zumstein to head the firm’s startup desk. The trio succeeds partners Christian Wyss, Damien Conus and Gian-Andrea Caprez, previous heads of the desk.
Tags :Luzius Zumstein
Vischer advised FimmCyte, a Swiss biotech developing targeted immunotherapies for chronic fibro-inflammatory diseases, in connection with its research collaboration and option-to-license agreement with Gedeon Richter, a pharmaceutical company specialised in women’s health, with headquarters
In a groundbreaking move, Boehringer Ingelheim has sealed the deal to acquire T3 Pharmaceuticals, a dynamic Swiss biotech company, for a staggering amount of up to 450 million CHF. This strategic move signals a major leap
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, has announced the completion of its oversubscribed Series C equity financing raising EUR 67.5m (USD 72m) from a syndicate
LASCCO, a biomedical-technology company, and Abionic, a nanotechnology company, both based at the Biopôle of Lausanne, entered into a licensing agreement with Fapon Biotech, a global leading life sciences company, based in Dongguan (China)
Vischer acted as legal advisor to LimmaTech Biologics as it successfully concluded a USD 37 million (CHF 33 million) Series A financing round, co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund.
Intel Capital, an investor in the future of compute, has invested in Unisers, a Swiss semiconductor metrology company that identifies invisible contamination-caused defects in semiconductor materials. The USD14 million seed financing round was led
Medartis, a Basel-based orthopedic company specializing in head and extremity surgery, recently signed an agreement with the private founders of KeriMedical, a Geneva-based private company specializing in the development and manufacture of implants for hand
Anokion, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, recently closed an USD 35 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative. Founded in Switzerland and based
Anaveon, a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well
